QuantHealth deepens clinical expertise through its development of AI solutions that solve the $45B annual clinical trial expenditure losses faced by life science companies worldwide
QuantHealth, an AI-powered clinical trial design company that simulates clinical trials, today announced the appointment of Dr. Adam Petrich, MD, as the company’s inaugural Chief Medical Officer and Adam Goldberger as Chief Financial Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207493899/en/
Dr. Adam Petrich, Chief Medical Officer (Photo: Business Wire)
Dr. Petrich, a medical oncologist and hematologist by training, has spent the last ten years in oncology drug development, including tenures of increasing responsibility at Daiichi-Sankyo and AbbVie, across various platforms and phases of clinical development. Prior to that, he was a full-time faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago. His role at QuantHealth will include enhancing product offerings and capabilities, providing oversight and guidance to the R&D teams, and leading all outward-facing clinically-oriented interactions.
As QuantHealth’s first Chief Financial Officer, Adam Goldberger will partner with the executive team to help drive innovation and reach critical financial milestones as the company continues commercializing its platform and expanding its roster of industry partners. Prior to QuantHealth, Adam spent more than two decades in various capacities within the private and public sectors, working for companies across Israel, The United States, and Australia. Most recently, he acted as Chief Business Officer at RenalSense and CFO/Group Executive at MedHealth.
"Having the right team in place is an essential component of ensuring QuantHealth becomes a ubiquitous piece of the drug discovery approval process," said Orr Inbar, Co-founder and CEO of QuantHealth. “We couldn't be more excited to have Dr. Petrich and Adam Goldberger joining us to help ensure the long-term scalability of our business while we continue to deliver the time efficiencies and cost savings the healthcare industry has come to expect from our trial simulations and synthetic trials."
These new appointments come on the heels of QuantHealth securing a strategic investment from Accenture Ventures and participation from a leading CRO firm and additional investors, bringing its Series A funding total to $17M. QuantHealth was founded in 2020 with a mission to help pharmaceutical companies accelerate and de-risk their programs by using AI to simulate clinical trials. The company uses AI to deliver real-world evidence by predicting the end result of a clinical trial, how the new drugs will work, and how patients may respond to therapeutics.
About QuantHealth
90% of drugs fail the clinical stage, representing a direct $45B annual waste to pharma companies. To address this challenge at its core, QuantHealth's Clinical-Simulator predicts how each patient in a clinical trial will respond to treatment, allowing trial design teams to predict how an entire clinical trial will play out and adapt accordingly. Based on its novel AI engine and a vast dataset of 350m patients and over 700K therapeutics, QuantHealth's simulator can predict clinical trial results with high accuracy, allowing users to answer mission-critical questions such as trial go/no-go, cohort optimization, drug repurposing, and more. QuantHealth was founded by healthcare experts who led commercial, product, and data science at various leading companies in the US and Israel. QuantHealth is backed by expert Life-Science investors in the US, Europe, and Israel and is supported by an advisory board of physicians and scientists from leading academic institutions. To learn more, visit https://quanthealth.ai/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207493899/en/
Contacts
SolComms
Greg Russo
quanthealth@solcomms.co
